a cure for hep c, aids, the flu and dengue..., page-89

This is exceptional news Tawnyport...the fact that it is an independent report again vindicates previous research /due diligence on Biotron.

I expect phase ll trials for hepC to confirm the effectiveness of bit225,this will be a trigger for a partnership or full takeover by one of the major pharmas(my guess would be Roche due to existing HepC medication synergies...this is pure speculation though).

TA and fundamentals suggest that these are about to step to the next level and with the limited free float available the greater market will be fighting hard to get hold of her at multiples of todays close.

Good day for the company and management.GL holders.